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The enzyme NUDT15 efficiently hydrolyzes the active me-
tabolites of thiopurine drugs, which are routinely used for
treating cancer and inflammatory diseases. Loss-of-function
variants in NUDT15 are strongly associated with thiopurine
intolerance, such as leukopenia, and preemptive NUDT15 gen-
otyping has been clinically implemented to personalize thio-
purine dosing. However, understanding the molecular
consequences of these variants has been difficult, as no struc-
tural information was available for NUDT15 proteins encoded
by clinically actionable pharmacogenetic variants because of
their inherent instability. Recently, the small molecule NUDT15
inhibitor TH1760 has been shown to sensitize cells to thio-
purines, through enhanced accumulation of 6-thio-guanine in
DNA. Building upon this, we herein report the development of
the potent and specific NUDT15 inhibitor, TH7755. TH7755
demonstrates a greatly improved cellular target engagement and
6-thioguanine potentiation compared with TH1760, while
showing no cytotoxicity on its own. This potent inhibitor also
stabilized NUDT15, enabling analysis by X-ray crystallography.
We have determined high-resolution structures of the clinically
relevant NUDT15 variants Arg139Cys, Arg139His, Val18Ile, and
V18_V19insGlyVal. These structures provide clear insights into
the structural basis for the thiopurine intolerance phenotype
observed in patients carrying these pharmacogenetic variants.
These findings will aid in predicting the effects of new NUDT15
sequence variations yet to be discovered in the clinic.
NUDT15 belongs to the NUDIX (nucleoside diphosphates
linked to a moiety x) superfamily of proteins, which are
characterized by containing a conserved NUDIX box motif
(GX5EX7REVXEEXGU, where U is a hydrophobic residue).
These enzymes metabolize a diverse range of substrates
including canonical (d)NTPs, oxidized (d)NTPs, nonnucleo-
side polyphosphates, and capped mRNAs (1). NUDT15 (also
known as MTH2) was originally proposed to have a similar
function to another NUDIX family member MTH1 (MutT
homolog 1), which efficiently hydrolyses oxidized nucleotides,
preventing their incorporation into DNA and thereby sani-
tizing the cellular nucleotide pool (2). However, it has been
shown that NUDT15 only displays weak activity toward
oxidized nucleotides and the true biological function of the
enzyme remains unknown (3, 4). Intriguingly, genome-wide
association studies identified NUDT15 mutations (such as
Arg139Cys) that are strongly associated with thiopurine
intolerance (5, 6). Further studies have conclusively shown that
NUDT15 efficiently hydrolyses active metabolites of thio-
purine drugs, such as 6-thio-(d)GTP, to their monophosphate
forms (4, 7).
Thiopurine drugs are metabolized into cytotoxic guanosine
analog metabolites and are commonly used for treating diseases
such as acute lymphoblastic leukemia (ALL), acute myeloid
leukemia (AML), and inflammatory bowel disease (8, 9).
Several different thiopurine drugs are used clinically, such as
6-mercaptopurine, 6-thioguanine (6-TG), and azathioprine.
These compounds are ultimately converted to the cellularly
active metabolites 6-thio-GTP and 6-thio-dGTP. After 6-thio-
dGTP is incorporated into DNA, it is methylated (10–12), and
following a second round of replication, a Me-6-thio-dG:T
mismatch is generated, leading to futile DNA repair attempts
and ultimately cell death (13, 14). Thiopurine treatment is
commonly associated with leukopenia. This is often a result of
genetic polymorphism in genes encoding proteins such as
thiopurine S-methyltransferase (TPMT), which inactivate thi-
opurines including 6-mercaptopurine and 6-TG. These vari-
ants in TPMT therefore lead to excessive accumulation of
thioguanine in the genome, which ultimately causes the severe
hematopoietic toxicity observed in patients undergoing
thiopurine-based chemotherapy (15–19). For this reason, it is
recommended to adjust the thiopurine dosage according to the
results of preemptive TPMT genotyping (20, 21).
Similar to TPMT, loss-of-function variants in NUDT15 are
also strongly associated with thiopurine toxicity, because of
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increased incorporation of 6-thio-dGTP into DNA. It is
becoming increasingly clear that thiopurine treatment strate-
gies need to include both NUDT15 and TPMT genotyping to
identify patients at-risk of hematopoietic toxicities (20). This is
a particularly important consideration for certain racial/ethnic
groups as loss-of-function NUDT15 variants are more com-
mon in people of Asian or Hispanic descent compared with
Caucasians (5). A recent study on a cohort of 270 children
diagnosed with ALL and treated with thiopurines identified
four mutations in the NUDT15 gene (7), which showed a
74.4% to 100% loss of activity, relative to the WT enzyme. The
identified mutations included three single point mutants
c.415C>T (Arg139Cys), c.416G>A (Arg139His), c.52G>A
(Val18Ile) and a fourth mutant c.36_37insGGAGTC (Val18_
Val19insGlyVal), where a microsatellite expansion results in an
in-frame insertion of two residues (glycine and valine). The
additional residues are inserted into a segment already con-
taining three glycine–valine repeats and the insertion therefore
extends this segment by a single Gly-Val repetition.
Based on the activity of NUDT15 toward 6-thio(d)GTP,
which reduces cellular thiopurine toxicity, recent studies have
also proposed NUDT15 inhibition as a means of improving
thiopurine therapy in patients with WT NUDT15. Specifically,
the first potent and selective small molecule NUDT15 inhib-
itor (TH1760) was recently shown to sensitize cells to thio-
purines, through the enhanced incorporation of 6-thio-dGTP
in DNA (22). This may increase the effectiveness of thiopurine
therapy by allowing lower doses of thiopurines to be used
while still maintaining good therapeutic effect. In this study,
we present the novel small-molecule NUDT15 inhibitor
TH7755, which has substantially improved cellular target
engagement as well as potentiation of 6-thio-guanine
compared to TH1760. We solved the crystal structure of WT
NUDT15 in complex with TH7755, which demonstrates that
TH7755 adopts a highly similar binding mode to TH1760.
Thermal shift analysis indicated that TH7755 significantly
increased the stability of NUDT15. No structural information
for clinically isolated NUDT15 mutations was previously
available because of their inherent instability, which renders
them very difficult to crystallize. We utilized the stabilizing
effect of TH7755 to determine high-resolution crystal struc-
tures of the clinically relevant NUDT15 mutants Arg139Cys,
Arg139His, Val18Ile, and V18_V19insGlyVal. Analysis of these
structures in relation to the WT enzyme provides clear ex-
planations for the detrimental phenotypic effects observed for
these NUDT15 variants.
Results
TH7755 is a potent NUDT15 inhibitor with improved cellular
activity
We synthesized the new NUDT15 inhibitor TH7755
based on our previously developed inhibitor TH1760.
TH7755 differs from TH1760 in that it contains two addi-
tional methyl groups, which are attached to the piperazine
ring system and the nitrogen of the indole group (Fig. 1A).
The inhibition of human and mouse NUTD15 by TH7755
was determined in vitro using a malachite green–based assay
(3, 4). The IC50 values of TH7755 for human and mouse
were 30 nM (pIC50 = 7.53 ± 0.03, n = 2) and 144 nM
(pIC50 = 6.84 ± 0.02, n = 2), respectively, (Fig. 1, B and C),
indicating that the affinity of the inhibitor is higher for the
human isoform of the enzyme. The IC50 value of TH7755 for
human NUDT15 is very similar to the IC50 value previously
reported for TH1760 (25 nM) (22).
To investigate the ability of TH7755 to engage with NUDT15
in cells, we used the cellular thermal shift assay (CETSA)method.
Intact AML HL-60 cells were incubated with either TH7755,
TH1760, or dimethyl sulfoxide (DMSO) only, after which the
cells were heated, lysed, and the thermal stability of cellular
NUDT15 was examined by Western blot analysis. At a concen-
tration of 10 μM TH7755 substantially stabilized cellular
NUDT15 from heat-induced denaturation and precipitation, as
indicated by an increase of 4 C for the apparent aggregation
temperature (Tagg) of NUDT15. Importantly, this significant
stabilization strongly suggests TH7755 binds to NUDT15 in the
cell (Fig. 1, D–F). In contrast, at the same concentration, the
inhibitor TH1760 only increased the Tagg of NUDT15 by 1 C.
The potency of target engagement by TH7755 was further
investigated using isothermal dose–response fingerprint CETSA
(ITDRFCETSA), where intact HL-60 cells were treated with
increasing concentrations of TH7755 before the thermal stability
of cellular NUDT15 was determined at a constant screening
temperature. TH7755 consistently engaged and thereby stabi-
lized cellular NUDT15, which was observed to start at a con-
centration of 1 μM and increased with increasing TH7755
concentration (Fig. 1, G and H). Collectively, our CETSA data
show that TH7755 engages efficiently with NUDT15 in HL-
60 cells and to a larger extent compared with TH1760.
Loss of NUDT15 activity/expression has yet to be asso-
ciated with an easily quantifiable phenotype. However, in-
hibition of NUDT15 6-thio-dGTPase activity leads to
thiopurine hypersensitivity, which we previously exploited to
analyze TH1760 (22). To further characterize TH7755, AML
HL-60 cells were treated with a dose–response concentra-
tion matrix of thiopurine (6-TG) and TH7755 for 4 days,
after which cell viabilities were determined using a resazurin
reduction cell viability assay. In agreement with its
biochemical inhibitory activity against NUDT15, TH7755
increased the cytotoxicity of 6-TG, as evidenced by a
decrease in the 6-TG cytotoxic EC50 (half maximal effective
concentration), starting from concentrations as low as
50 nM. Importantly, TH7755 did not demonstrate measur-
able cytotoxicity when applied alone up to a concentration of
100 μM (Fig. 2, A and B). In agreement with the CETSA data,
showing that TH7755 displays an enhanced ability to engage
cellular NUDT15 compared with TH1760 (Fig. 1, D–F),
TH7755 also displays a far superior in-cell activity as
measured by 6-TG potentiation. TH7755 was shown to
strongly synergize with 6-TG in NUDT15-proficient AML
NB4 cells, which was effectively abrogated upon shRNA-
mediated NUDT15 depletion, indicating that TH7755
enhanced 6-TG efficacy through specifically inhibiting
NUDT15 (Fig. 2, C and D).
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TH7755 is a competitive inhibitor of NUDT15
To investigate the mode of inhibition of TH7755, we pro-
duced enzyme saturation curves of NUDT15, with 6-thio-
dGTP as substrate, at five different TH7755 concentrations
and determined kcat and Km values (Fig. S1, Table S1). We
analyzed the dependence of kcat and Km on TH7755 concen-
tration and found that while the Km clearly increased with
increasing TH7755 concentration (Fig. S1B), the kcat remained
unaltered (Fig. S1C), indicative of a competitive mode of in-
hibition. The Ki for TH7755 was determined to be 10.2 ±
Figure 1. In vitro and in vivo inhibition of NUDT15 by TH7755. A, chemical structures of TH1760 and TH7755, with their differences highlighted in red. B
and C, inhibition curves of human (B) and mouse (C) NUDT15 with TH7755. X-axis: [TH7755 concentration], y-axis: percentage activity of NUDT15. In all
experiments, formed Pi was determined by addition of malachite green reagent followed by measurement of absorbance at 630 nm. IC50 values were
determined using nonlinear regression in GraphPad Prism. The shown IC50 values represent the geometric mean (n = 2). D–F, CETSA of TH7755 and TH1760
in AML HL-60 cells. Intact HL-60 cells were treated with 10 μM TH7755, TH1760, or equal volume of DMSO for 3 h before cells were heated, lysed, and
subjected to Western blot to examine soluble NUDT15 and SOD-1 levels. D, The mean signals ± SD of soluble NUDT15 levels are shown, relative to SOD-1
levels and normalized to a DMSO control sample. Two independent experiments are shown. E, Tagg values (C) calculated from the signals in D, using the
Boltzmann sigmoid equation in GraphPad Prism. Two independent experiments are shown. F, corresponding Western blot analysis. G and H, potent
engagement of cellular NUDT15 by TH7755 as shown by ITDRFCETSA. Intact HL-60 pInducer20-3xHA-NUDT15 WT cells were induced with doxycycline
overnight before being treated with increasing concentrations of TH7755. Cells were heated, lysed, and subjected to Western blot to examine soluble
NUDT15 and SOD-1 levels. G, soluble HA-tagged NUDT15 levels, relative to SOD-1 levels and normalized to a DMSO control sample. H, corresponding
Western blot analysis. CETSA, cellular thermal shift assay; DMSO, dimethyl sulfoxide; ITDRFCETSA, isothermal dose–response fingerprint CETSA.
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0.9 nM in agreement with our calculated IC50 value for the
compound.
TH7755 recognition by WT NUDT15
To analyze the inhibitory mechanism of TH7755, we
determined the crystal structure of WT NUDT15 in com-
plex with the inhibitor at a resolution of 1.6 Å. The overall
structure of NUDT15 is a homodimer (Fig. 3A), consistent
with size-exclusion chromatography and small-angle X-ray
scattering experiments that show the enzyme is also dimeric
in solution (3). The NUDT15 monomer is comprised of two
alpha-helices (α1 and α2), seven beta-strands (β1–β7), and
four 310 helices (η1–η4) (Fig. 3B). The individual monomers
of NUDT15 have a classic NUDIX fold and are very similar
to one another, as indicated by the low RMSD value of
0.47 Å for their corresponding Cα-atoms. Each active site
contains clear density for a single TH7755 molecule, which
is positioned deep within the binding pocket (Fig. 3C).
TH7755 is coordinated by extensive hydrophobic and
hydrogen bond interactions. The benzoxazolone moiety of
TH7755 forms two direct hydrogen bonds with the main
chain nitrogen atoms of Gly137 and Leu138 and is further
supported by hydrophobic interactions with Leu45 and
Phe135. The sulfonamide group of TH7755 is positioned by
two interactions involving the main chain nitrogen of Val16
and the main chain oxygen of Thr94. The piperazine ring
system of the compound is positioned exclusively by hy-
drophobic interactions from the residues Phe135, Tyr94,
and His49. The piperazine ring has attained a chair
conformation with the N-substituents in semi-equatorial
orientations. This combined with its absolute R configura-
tion forces the adjacent 2-methyl group on the piperazine
into an axial orientation. The amide oxygen of TH7755
engages in water-mediated interactions with Arg34, which
itself interacts with the side chain of Gln44 and the main
chain oxygen of Val38. Finally, the indole group of the in-
hibitor is positioned by a perpendicular π-stacking interac-
tion with Tyr90 and is further stabilized by hydrophobic
interactions with Val38, Phe135, and Trp136 (Fig. 3C).
Comparison of NUDT15-TH7755 with the previously re-
ported NUDT15–TH1760 complex (22) shows that the
overall structures superimpose very well, with a low RMSD
value of 0.51 Å. There are no significant differences between
the two structures with the exception of minor variations in
two flexible loop regions. The overall binding mode of
TH7755 is highly similar to TH1760, with the surrounding
Figure 2. TH7755 is a cell-active NUDT15 inhibitor as evidenced by thioguanine potentiation. A, cell viability testing of TH7755 in AML HL-60 cells,
showing no cytotoxicity up to 100 μM. HL-60 cells were treated with TH7755 for 4 days before cell viabilities were determined using a resazurin viability
assay. Mean viabilities ±SD of a single experiment performed in duplicate are shown. B, TH7755 potentiated the antileukemic efficacy of thioguanine (6-TG)
in a dose-dependent manner, starting from 0.05 μM. HL-60 cells were treated with a dose–response concentration matrix of 6-TG and NUDT15 inhibitor
(TH7755 or TH1760) for 4 days before viabilities were determined. Mean viabilities ± SD of a single experiment performed in duplicate is shown. C and D,
NUDT15 depletion abrogated TH7755-induced 6-TG potentiation in AML NB4 cells. NB4 cells expressing doxycycline-inducible shRNA constructs, NUDT15-
specific (shN15) or control (shNT), were induced with doxycycline for 3 days before being treated with a dose–response concentration matrix of 6-TG and
TH7755. C, mean viabilities of two experiments performed in duplicate are shown. D, Left panel, the cytotoxic EC50 of 6-TG estimated from the mean
viabilities determined in C and calculated using a nonlinear curve fitting model with variable slope in GraphPad Prism. Right panel, knockdown efficiency of
shN15 shRNA in NB4 cells at 120 h postdoxycycline treatment.
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active site residues superimposing well between the struc-
tures (Fig. 3D). An interesting point of difference however is
the indole ring system, which in TH7755 is flipped 180
relative to the TH1760 structure, likely a result of the
additional methyl group present on the indole group of
TH7755.
TH7755 substantially increases the thermal stability of
NUDT15 variants
To determine whether inhibitor and substrate binding has a
significant stabilizing effect on WT and clinically relevant
NUDT15 variants (R139C, R139H, V18I and
Figure 3. Crystal structure of the NUDT15 TH7755 complex. A, crystallographic structure of dimeric NUDT15. Individual monomers are shown as ribbon
representations, colored cyan and green. The TH7755 ligands are depicted as stick models; C atoms are colored yellow, O atoms red, N atoms blue, and S
atoms gold. B, ribbon representation of the NUDT15 monomer in complex with TH7755. The secondary structure elements, alpha-helices (α1-2), beta-strands
(β1-7), and 310-helices (η1-4) are labeled. C, hydrogen bond network for TH7755 in the NUDT15 active site. Amino acids involved in ligand coordination are
depicted as sticks. Important water molecules are shown as red spheres. Hydrogen bond interactions are shown as dashed lines. The 2Fo − Fc electron density
map around TH7755 is contoured at 1.5 σ, and the Fo − Fc electron density map is contoured at 3.0 σ. D, comparison of NUDT15–TH7755 (cyan) with
NUDT15 in complex with TH1760 (white, PDB ID: 6T5J). TH1760 is depicted as a stick model; C atoms are colored magenta, O atoms red, N atoms blue, and S
atoms gold.
Figure 4. Thermal stability and activity analysis of WT NUDT15 and NUDT15 mutants. Differential scanning fluorimetry was used to determine the
thermal stability of wildtype NUDT15 (WT) and the mutant NUDT15 constructs R139C, R139H, V18I, and V18_V19insGV (INS). A, melting temperatures (Tm)
for each NUDT15 construct in the absence (black) or presence of either 6-Thio-GTP (yellow), TH7755 (green), or TH1760 (blue) are shown. The calculated Tm
values represent mean values from three independent experiments ± SD, which were plotted in GraphPad Prism. B, activity of wildtype NUDT15 and
NUDT15 mutants in the presence of 25 μM 6-thio-dGTP. Formed Pi was determined by addition of malachite green reagent followed by measurement of
the absorbance at 630 nm. The activities of mutant NUDT15 constructs were normalized to the activity of wildtype NUDT15 and plotted in GraphPad Prism.
Experiments were performed in triplicate.
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Val18_Val19insGlyVal), we obtained thermal stability data
using the technique differential scanning fluorimetry. In the
absence of substrate (6-thio-GTP) or inhibitor (TH7755), all
four mutant constructs were less thermally stable compared
with WT NUDT15, as indicated by their lower melting tem-
peratures (Tm) (Fig. 4A). The R139C and R139H mutants had
larger decreases in Tm compared with WT NUDT15 (−9.4
and −8.2 C, respectively) compared with the V18I and
Val18_Val19insGlyVal constructs (−3.7 and −1.8 C, respec-
tively). Addition of 6-thio-GTP resulted in a similar stabiliza-
tion for all of the constructs, with an average increase in Tm
of +5 C (Fig. 4A). TH7755 inhibitor binding had an even more
impressive stabilizing effect on the protein, with an average
increase in Tm of +11 C for WT and mutant NUDT15
(Fig. 4A). We also performed thermal stability tests with the
previously published inhibitor TH1760, which also signifi-
cantly stabilizes the enzyme, with an average Tm increase
of +11.5 C for WT and mutant NUDT15 (Fig. 4A).
NUDT15 mutants display lower enzymatic activity relative to
WT
In addition to investigating the thermal stability, we also
tested the enzymatic activity of the WT and mutant NUDT15
constructs in vitro. The R139C, R139H, V18I, and
Val18_Val19insGlyVal mutants all displayed reduced enzy-
matic activity relative to WT NUDT15, with a reduction in
activity ranging from 65 to 85% (Fig. 4B). The NUDT15
mutant R139H was least active, followed by Val18_Val19ins-
GlyVal, R139C, and lastly, V18I.
Structure determination of clinically relevant NUDT15 mutants
Before this study, no structures of clinically relevant
NUDT15 mutants had been determined, as their inherent
instability rendered them difficult to crystallize. Previous
studies aimed at elucidating the structural mechanisms that
affect protein stability therefore had to draw conclusions based
on WT NUDT15 structures, instead of using actual mutant
NUDT15 structural data. By utilizing the impressive stabilizing
effect of TH7755 on NUDT15, we were able to grow high-
quality crystals and solve high-resolution crystal structures of
the clinically relevant mutants R139C, R139H, V18I, and
V18_V19insGV (Fig. 2, A–C). These NUDT15 variant struc-
tures are highly structurally similar to WT NUDT15-TH7755,
as indicated by the low RMSD values for their corresponding
Cα-atoms values of 0.47, 0.42, 0.45, and 0.44 Å, respectively.
Comparison of these structures with WT NUDT15 in complex
with TH7755 provides clear insights into the structural rea-
sons for their reduced stability.
Figure 5. Crystal structures of the clinically relevant NUDT15 single-point mutations R139C, R139H, and V18I. The NUDT15 monomer of each mutant
structure is shown as a cyan cartoon ribbon representation. The top panels show the hydrogen bond networks of (A) R139C, (B) R139H, and (C) V18I. The
2Fo − Fc electron density maps for the mutated amino acids are contoured at 1.5 σ, and the Fo − Fc electron density maps are contoured at 3.0 σ. Hydrogen
bond interactions are shown as dashed lines. Amino acids are depicted as sticks; C atoms are colored cyan, O atoms red, N atoms blue, and S atoms gold. The
lower panels (D–F) show superpositions of each NUDT15 mutant (cyan) with wildtype NUDT15 in complex with TH7755 (white). The relevant secondary
structure elements, α2, β1, β4, and η3 are also highlighted.
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We first solved the structure of the most common phar-
macogenetic variant in NUDT15, R139C, to 1.4 Å resolution.
The side chain of Cys139 (located in α2) adopts two confor-
mations, one of which interacts with the main chain oxygen
atoms of both Leu131 (located in η3) and Leu134 (located in a
loop connecting α2 to η3) at distances of 3.2 and 3.4 Å,
respectively (Fig. 5A). In our structure of WT NUDT15 in
complex with TH7755, Arg139 forms interactions similar to
what is observed in the R139C structure. This involves a single
interaction with the main chain oxygen of Leu131 (at a dis-
tance of 2.9 Å) and two interactions with the main chain ox-
ygen of Leu134 (at distances of 2.9 and 3.2 Å, respectively).
Comparison of the R139C mutant structure with WT
NUDT15 shows that α2 superimposes very well between the
structures. However, in WT NUDT15, the 310-helix η3 is
shifted slightly closer to α2, than what is observed in the
mutant structure (Fig. 5D).
We then determined the structure of another clinically
relevant NUDT15 variant at position 139, the R139H, which
we solved to 1.6 Å resolution. In contrast to WT and NUDT15
R139C where residue 139 is capable of interactions with both
Leu131 and Leu134, the side chain of His139 only interacts
with the main chain oxygen of Leu134, at a distance of 3.2 Å
(Fig. 5B). As was observed for the R139C structure, compari-
son of R139H with WT NUDT15 shows α2 to superimpose
very well between the structures, while the 310-helix η3 is
positioned closer to α2 in the WT enzyme (Fig. 5E).
We then solved the structure of the V18I variant to 1.5 Å
resolution. Val18 is close to the dimer interface of NUDT15
and lies on the opposite side of the monomer relative to
position 139, which is solvent exposed. The V18 site is located
in β1 and is in close proximity to residues from the conserved
NUDIX motif, which itself is comprised of a small beta-sheet
(β4) linked by a loop region to an alpha-helix (α1). In our
V18I mutant structure, the side chain of Ile18 is surrounded by
residues from α1 (Thr64, Ala60, and Glu63), β1 (Val20), β4
(Gly47), β5 (Leu72) as well as the loop region connecting β4
and β5 (Pro46) (Fig. 5C). Comparison of the V18I mutant
structure with WT NUDT15 shows that the secondary struc-
ture in this region superimposes very well between the pro-
teins. However, the additional methyl group present in the side
chain of Ile18 slightly disrupts the favorable hydrophobic
packing interactions with Pro46, Gly47, and Glu63, which are
present in the WT structure with its smaller valine side chain
(Fig. 5F).
Finally, we solved the structure of the NUDT15
V18_V19insGV mutant to a resolution of 1.5 Å. The
V18_V19insGV mutation leads to an in-frame insertion of the
residues glycine and valine into a segment on β1 that already
contains three GlyVal repeats, thus extending it by one repe-
tition (Fig. 6, A and B). While the residues Gly15 to Val20 in
NUDT15 V18_V19insGV occupy the same position as Gly13
to Val18 in the WT structure, the insertion leads to the pre-
ceding residues being out of frame with one another (Fig. 6B).
Comparison of the mutant structure with WT NUDT15 shows
that β1 superimposes well between the structures. However, as
mentioned above, the preceding sequence is out of frame, and
the two structures therefore begin to diverge in direction of the
N terminus (Fig. 6C). Unfortunately, as the residues at the very
beginning of the N termini are disordered in both structures, a
Figure 6. Crystal structure of the clinically relevant NUDT15 insertion mutation V18_V19insGlyVal. A, crystal structure the NUDT15 V18_V19insGV
dimer in complex with TH7755. Individual monomers are shown as ribbon representations, colored cyan and green. In each monomer, the glycine–valine
repeats which include the insertion mutation are shown in orange. B, sequence comparison highlighting the difference between wildtype NUDT15 and
NUDT15 V18_V19insGV. The Gly–Val repeats are shown in orange, and the additional Gly–Val repeat present in the mutant sequence is highlighted bold.
The surrounding sequence, which is identical in both proteins, is shown in cyan. C, comparison of NUDT15-the NUDT15 V18_V19insGlyVal dimer (cyan and
green) with wildtype NUDT15 in complex with TH7755 (white). The 2Fo − Fc electron density map for the Gly–Val repeats (shown as orange sticks) in NUDT15
V18_V19insGlyVal is contoured at 1.5 σ, and the Fo − Fc electron density map is contoured at 3.0 σ. The residues Gly13, Val14, Phe54, and His93 from
NUDT15 V18_V19insGlyVal correspond to Arg11, Pro12, Phe52, and His91 in wildtype NUDT15.
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full analysis of the structural divergence in this area is not
possible. An important difference between the proteins is the
residue Val14 in V18_V19insGV NUDT15, which aligns with
Pro12 in the WT enzyme (Fig. 6C). Furthermore, as the
insertion results in the N-terminal sequences being out of
alignment, Pro12 is actually positioned closer the N-terminal
end in the NUDT15 V18_V19insGV structure, relative to WT
NUDT15.
Discussion
Thiopurine drugs are routinely used for treating cancer and
inflammatory diseases (8, 9). Side-effects such as hematopoi-
etic toxicity are common in patients treated with these drugs,
often a consequence of loss of function mutations in genes
encoding proteins that metabolize thiopurines such as TPMT
(16). In recent years NUDT15 has also been shown to be a
major player in thiopurine metabolism. Inactivating mutations
in NUDT15 are strongly associated with thiopurine toxicity
(19), and thiopurine dosage adjustment is recommended based
on NUDT15 genotyping (20, 21). In addition to the role of
NUDT15 in thiopurine hypersensitivity, other studies have
suggested that thiopurine-based therapies in patients with WT
NUDT15, can be improved by NUDT15 inhibition. Recently,
we reported that a small molecule NUDT15 inhibitor
(TH1760) sensitizes cells to thiopurines (22). A combination
treatment might allow for lower thiopurine doses to be
administered while still maintaining good therapeutic effect,
potentially reducing toxic side-effects during treatment. To
obtain a NUDT15 inhibitor with improved activity in cells, we
developed the small-molecule NUDT15 inhibitor (TH7755)
based on our previously developed inhibitor TH1760. We then
utilized the excellent stabilizing properties of TH7755 to solve
the structures of several clinically relevant NUDT15 mutants.
TH7755 greatly stabilizes the active site of NUDT15, as evi-
denced by the fact that the WT NUDT15-TH7755 and
NUDT15 variant-TH7755 complexes superimpose well in this
region (Fig. S2).
The novel NUDT15 inhibitor TH7755 differs from TH1760
in that it contains two additional methyl groups, which are
attached to the piperazine ring system and the nitrogen of the
indole group. Our assay data indicated that TH7755 was a
slightly weaker inhibitor in vitro than TH1760. However,
TH7755 actually displayed far superior cellular potency
compared with TH1760. As passive cell permeability by small
molecules is usually favored by increased lipophilicity (23), the
superior cellular effect of TH7755 may be because of its slight
increase in lipophilicity (cLogP 2.05) relative to TH1760
(cLogP 1.41). Superposition of our WT NUDT15–TH7755
structure with the previously determined NUDT15–TH1760
complex (22) indicated that the inhibitors have almost iden-
tical binding modes. A notable difference, however, is the
indole group of TH7755, which is flipped 180 relative to its
position in the TH1760 structure. This is likely caused by the
additional methyl group attached to the indole nitrogen of
TH7755. Comparison of the two structures also provides in-
sights into their slight differences in inhibition in vitro. While
there is sufficient space in the binding pocket to accommodate
both methyl groups of TH7755, their addition does bring the
inhibitor into closer proximity with some ligand coordinating
residues than what is observed in the TH1760 structure. First,
the methyl group brings in the piperazine ring system into
closer range of Phe135, and second, the methyl group bound
to the indole nitrogen brings it closer to the main chain oxygen
atoms of Glu88 and Asn89. The latter would present an un-
favorable environment for a hydrophobic methyl group, which
may explain why TH7755 displays slightly weaker NUDT15
inhibition than TH1760, which lacks a methyl at this position.
We also tested the inhibitory potency of TH7755 against
mouse NUDT15 (mNUDT15), which is relevant because
further development of the inhibitor would likely require
testing in mice before human clinical trials. Interestingly,
TH7755 was significantly less active against mouse NUDT15
compared with human NUDT15 (hNUDT15). As there is no
structure of mouse NUDT15 available, we compared the
protein sequences of mNUDT15 and hNUDT15 using Clustal
Omega through the EBI webserver (24). Overall, the enzymes
are highly similar, sharing 91% amino acid sequence identity.
We analyzed the residues required for inhibitor binding in our
hNUDT15–TH7755 structure and found two differences be-
tween the structures (Fig. S3). These differences are at posi-
tions Val38 and Gly137 in hNUDT15, which correspond to
Phe37 and Ala136 in mNUDT15. In our human structure,
Val38 provides a hydrophobic interaction with the indole
group of TH7755, whereas Gly137 hydrogen bonds with the
benzoxazolone moiety of the inhibitor through its main chain
nitrogen atom. As these amino acid substitutions in
mNUDT15 are bulkier and more hydrophobic, we propose
this to be a contributing factor for the weaker inhibition of the
mouse enzyme.
Before this study, there was no structural information for
clinically relevant NUDT15 mutants as their lack of stability
rendered them extremely difficult to crystallize. In the current
study, we were able to use the impressive stabilizing effect of
TH7755 to solve the structures of four clinically isolated
NUDT15 variants (R139C, R139H, V18I and V18_V19ins-
GlyVal). In the absence of inhibitor, our thermal stability data
showed R139C to be the least stable variant, followed by
R139H, V18I and finally Val18_Val19insGlyVal. This trend
agrees with previously published thermal stability data by
Moriyama et al. (7), who identified these four NUDT15 mu-
tations in a cohort of 270 children diagnosed with ALL and
treated with thiopurines. We also tested the enzymatic activity
of the mutant NUDT15 constructs, all of which showed clearly
lower enzymatic activity relative to the WT enzyme, with
values ranging from 65% to 85%. The previously mentioned
Moriyama et al. (7) study also showed large decreases in
enzyme activity for all four mutants, ranging from 74 to 100%
inactivity, relative to WT NUDT15. Interestingly, in that study,
the R139C mutant was reported to be completely inactive,
which contrasts with a different study by Valerie et al. (4)
showing the activity of R139C to be comparable to WT
NUDT15. However, it should be noted that the Valerie et al.
study did show NUDT15 R139C to be highly unstable, which
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agrees with our results and those of Moriyama et al. The
discrepancies in enzymatic activity may in part result from the
choice of buffers used during protein purification and enzy-
matic assays, which can have a profound effect on protein
stability and activity.
Analysis of our NUDT15 mutant structures in relation to
the WT enzyme allowed us to assess the underlying structural
reasons for their diminished stability. These structures also
highlight the importance of analyzing experimentally deter-
mined structures when drawing conclusions about the struc-
tural effect a mutation has on an enzyme. It was previously
proposed on the basis of the WT NUDT15 structure that the
R139C mutation might lead to the formation of a disulphide
bond between the mutated residue and the neighboring res-
idue Cys140 (3). This would have resulted in the distortion of
an α-helix (α2), which could explain the instability of the
R139C mutant. In our structure, the sulfhydryl group of
Cys139 points away from C140, and no disulphide bond is
formed. Instead, the side chain has a dual conformation, one of
which interacts with the main chain of Leu131 (η3) and
Leu134 (loop connecting α2 to η3), similar to what was
observed in our R139H structure, where the side chain of
His139 also interacts with the main chain of Leu134 (but not
Leu131). In our WT NUDT15 structure, Arg139 also interacts
with the main chain oxygen atoms of Leu131 and Leu134;
however, the bond distances are shorter than what is observed
in the R139C and R139H mutants. This results in η3 being
pulled closer to α2 in the WT structure. Clearly, the role of the
arginine at this position is to stabilize the position of η3 as well
as the loop which connects it to α2. This region of the protein
is flexible and solvent exposed, explaining why mutations here
are so destabilizing. Based on these structures, we believe that
while these mutants are still capable of interacting with Leu131
and Leu134, they are unable to interact with these residues as
tightly as Arg139, which has a more electronegative side chain
because of its three nitrogen atoms. In addition, the sulfur
atom in the side chain of Cys139 is less electronegative than
the single nitrogen atom from His139, making it less stabiliz-
ing and potentially explaining why the R139C mutant is less
thermally stable than R139H.
Analysis of our V18I and Val18_Val19insGlyVal structures
also provided insights into their reduced stability and activity
compared with WT NUDT15. In the case of the V18I mutant,
the additional methyl group in the side chain of Ile18 results in
less favorable hydrophobic interactions with Pro46 (loop re-
gion connecting β4 and β5), Gly47 (β4), and Glu63 (α1)
compared with the WT enzyme with its smaller valine side
chain. This could result in slight destabilization of the NUDIX
motif, which itself is comprised of a small beta-sheet (β4)
linked by a loop region to an alpha-helix (α1). This highly
important motif contains residues responsible for the coordi-
nation of magnesium and water molecules involved in sub-
strate hydrolysis (1, 3), explaining why the V18I mutation
negatively affects both NUDT15 stability and enzyme activity.
With regard to our Val18_Val19insGlyVal structure, the
Gly–Val insertion results in the first 12 residues of the protein
sequence being out of frame with the WT enzyme, meaning
that the two structures begin to physically diverge in direction
of the N terminus. A significant difference in the mutant
structure is Val14, which aligns with Pro12 in the WT
NUDT15. Pro12 (note that both proteins have the same
numbering for this residue) is positioned closer to the N-ter-
minal end in the NUDT15 V18_V19insGV structure. The
unique structural properties of proline strongly influence the
protein main chain geometry and protein stability. Further-
more, in WT NUDT15, Pro12 forms a CH/π interaction with
His91 (located on β6), and it is also within range of a hydro-
phobic interaction with Phe52, which is located in a loop be-
tween β4 and α1 from the second monomer. The valine side
chain in the mutant structure is not capable of a CH/π
interaction with its neighboring histidine residue. Interference
with β6 would likely have a destabilizing effect because of its
importance for stabilizing the NUDT15 core, whereas intro-
ducing strain to β4 would interfere with residues of the
NUDIX motif and therefore negatively impact enzyme activity.
As mentioned earlier, while the V18I and Val18_Val19ins-
GlyVal proteins are less stable than WT NUDT15, they are still
significantly more stable than the R139C and R139H mutants.
This may be because of the fact these mutations are located
closer to the dimer interface (which stabilizes NUDT15 in
solution and these mutations would be unlikely to disrupt it),
whereas the variants at position 139 are needed to stabilize a
310-helix (in a flexible solvent exposed region), which is highly
sensitive to mutations. However, it should also be noted that
the V18I mutation presented here is a relatively conservative
mutation and mutations to something much larger (i.e., tryp-
tophan) or significantly charged (i.e., arginine) have previously
been shown to be severely destabilizing (21).
In conclusion, we present the development of TH7755, a
potent NUDT15 inhibitor with improved cellular potency,
which allowed us to determine the structures of four clinically
relevant NUDT15 mutants. Analysis of this structural infor-
mation provided explanations for the detrimental phenotypic
effects observed for these variants. TH7755 will provide a
valuable tool for future studies of clinically relevant loss-of-
function NUDT15 variants and has the potential to be useful
in a clinical setting because of its ability to increase the
effectiveness of thiopurine therapy.
Experimental procedures
NUDT15 purification
WT NUDT15 was expressed and purified as previously
published (3). The NUDT15 mutants R139C, R139H, V18I,
and V18_V19insGV were produced, as described by Moriyama
et al. (7). Briefly, human NUDT15 cDNA was cloned into a
pCold II expression vector with an N-terminal His tag. The
NUDT15 mutations analyzed in this study were then intro-
duced into this vector via site-directed mutagenesis. All con-
structs were expressed in E. coli BL21 cells and purified to
homogeneity by immobilized metal affinity chromatography
followed by size-exclusion chromatography. Purified proteins
were concentrated in sample buffer (10 mM Tris-HCl, 0.1 mM
EDTA, 5 mM DTT, 10% (v/v) glycerol pH 8.0) after which the
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buffer was exchanged to the final storage buffer (20 mM
HEPES pH 7.5, 100 mM NaCl, 10% glycerol, and 1 mM TCEP).
The samples were then flash frozen in liquid nitrogen, and
stored at −80 C.
Crystallization and data collection
All proteins (20 mg/ml) were crystallized via hanging drop
vapor diffusion at 21 C in 0.1 M Tris pH 8.0, 0.2 M sodium
acetate, 38% PEG 4000 (WT NUDT15), 0.12 M mono-
saccharide mix (0.2 M D-Glucose, 0.2 M D-Mannose, 0.2 M
D-Galactose, 0.2 M L-Fucose, 0.2 M D-Xylose, 0.2 M N-
Acetyl-D-Glucosamine), 0.1 M imidazole/MES pH 6,5, 12.5%
MPD, 12.5% PEG 1000, 12.5% PEG 3350 (R139C), 0.1 MMMT
pH 5.0, 25.4% PEG 1500 (R139H), 0.12 M monosaccharide
mix, 0.1 M imidazole/MES pH 6.5, 20% PEG 500 MME, 20%
PEG 2000 (V18I), and 0.09 M SPG pH 5.0, 22.25% PEG 1500,
0.01 M sodium/potassium phosphate, 2.75% 1,2 propandiol,
1.0% glycerol (V18_V19insGV). The R139H crystals were
soaked in cryoprotectant solution containing 0.1 M MMT pH
5.0, 30% PEG 1500, 20% ethylene glycol, 2 mM TH7755 for
10 min, and then flash frozen in liquid nitrogen. Diffraction
quality crystals appeared after 1 week.
X-ray diffraction data were collected on the BioMAX
beamline at MAXIV and the I24 beamline of the Diamond
Light Source. The datasets were collected at 100 K at a
wavelength of either 0.976 Å (NUDT15 R139C, R139H and
V18I), 0.918 Å (WT NUDT15) or 0.968 Å (NUDT15
V18_V19insGV). Single crystals were used for data collection,
with the exception of the R139H structure where data from
two crystals were collected and later merged.
Structure determination and refinement
All datasets were indexed and integrated using DIALS
(v3.2.2) (25), followed by scaling using AIMLESS (26) within
the CCP4 suite (27). Structures were solved via molecular
replacement with Phaser (28) using the monomer of a WT
NUDT15 structure (PDB ID: 5LPG) as the search model.
Translation libaration screw parameters were determined us-
ing the TLSMD webserver (29). Several rounds of manual
model building and refinement were performed using Coot
(30), phenix.refine (31) and REFMAC (32) during which waters
and ligands were incorporated into the structure. Data pro-
cessing and refinement statistics are presented in Table 1. The
coordinates and structure factors for WT NUDT15-TH7755
and the mutant structures V18I, R139C, R139H, and
V18_V19insGV were deposited in the PDB under the codes
7B63, 7B64, 7B65, 7B66, and 7B67, respectively.
Thermal stability tests for WT NUDT15 and NUDT15 mutants
The stability of WT NUDT15 and the R139C, R139H, V18I,
and V18_V19insGV variants was examined using differential
scanning fluorimetry (33). Each assay condition contained
10 μM protein in sample buffer (20 mM HEPES, 300 mM
NaCl, 10% glycerol, 5 mM MgCl2 pH 7.5) with 10X SYPRO
Orange dye (Thermo Fisher Scientific), and either 1 mM
6-thio-GTP, 0.1 mM TH7755, or a buffer only control. Ex-
periments were performed using a StepOne real time PCR
machine (Applied Biosystems) where the temperature was
increased from 25 to 95 C at a rate of 1 C/min. The melting
temperatures (Tm) were then determined in the Applied Bio-
systems Protein Thermal Shift Software using the Boltzmann
Table 1
Data collection and refinement statistics




MAXIV BioMAX MAXIV BioMAX MAXIV BioMAX MAXIV BioMAX DLS I24
Space group P 1 21 1 C 1 2 1 P 1 P 1 P 1 21 1
Cell dimensions
a,b,c (Å) 63.6, 45.6, 67.0 115.5, 34.6, 75,2 34.9, 43.8, 60.4 41.3, 60.2, 69.3 63.4, 45.7, 66.3
α, β, γ () 90, 116, 90 90.0, 148.6, 90.0 91.6, 106.7, 113.48 100.1, 104.1, 90.3 90, 115.1, 90
Resolution (Å) 60.24–1.60 (1.63–1.60)a 39.22–1.50 (1.53–1.50)a 35.37–1.60 (1.63–1.60)a 40.59–1.60 (1.63–1.60)a 60.07–1.45 (1.47–1.45)
Rmeas 0.064 (0.721)a 0.119 (0.886)a 0.059 (0.148)a 0.060 (0.305)a 0.086 (1.458)a
Rpim 0.034 (0.385)a 0.062 (0.472)a 0.042 (0.105)a 0.042 (0.216)a 0.021 (0.362)1
CC1/2 0.999 (0.862)a 0.994 (0.949)a 0.997 (0.985)a 0.998 (0.976)a 1.000 (0.861)a
<I/σ(I)> 15.1 (2.4)a 8.6 (1.8)a 16.2 (7.6)a 11.5 (2.7)a 24.7 (3.1)a
Total observations 310,958 (15,401)a 166,790 (8167)a 140,950 (6.909)a 289,021 (14,047)a 1,931,455 (93,528)a
Unique observations 45,919 (2312)a 25,129 (1235)a 39,574 (1931)a 81,339 (3976)a 61,265 (3026)a
Completeness (%) 100 (100)a 100 (100)a 96.6 (95.2)a 96.8 (95.3)a 100 (100)a
Redundancy 6.8 (6.7)a 6.6 (6.6)a 3.6 (3.6)a 3.6 (3.5)a 31.5 (30.9)a
Refinement
Rwork/Rfree 0.167/0.196 0.180/0.213 0.160/0.184 0.185/0.220 0.167/0.197
B-factors (A2):
Protein 25.5 42.3 23.1 33.1 21.4
Solvent 37.6 51.8 34.8 27.2 35.6
Ligand 20.2 39.8 24.0 39.0 17.5
R.m.s.d. bond lengths (Å) 0.01 0.01 0.01 0.01 0.01
R.m.s.d. bond angles () 1.82 1.74 1.89 1.70 1.86
Ramachandran statistics:
Favored (%) 98.1 96.7 98.7 97.6 98.71
Outliers (%) 0 0 0 0 0.32
PDB ID 7B63 7B64 7B65 7B66 7B67
a Values in parentheses are for the highest-resolution shell.
Structural basis for thiopurine sensitivity
10 J. Biol. Chem. (2021) 296 100568
model. Data were collected from three separate experiments
and plotted using GraphPad Prism software.
Cellular thermal shift assay
CETSA and ITDRFCETSA were performed as described
previously (22, 34). HL-60 cells were treated with putative
NUDT15 inhibitors or a DMSO only control for 3 h at 37 C
and 5% CO2 in a humidified incubator, after which cells were
harvested, washed by PBS, and then resuspended in TBS
supplemented with protease inhibitors. Cell suspensions were
then heated at indicated temperatures for 3 min in a Veriti 96-
well Thermal Cycler (ABI), followed by cell lysis with three
freeze-thaw cycles. Cell lysates were then clarified by centri-
fugation and prepared for SDS-PAGE and Western blot
analysis. For ITDRFCETSA HL-60 cells were transduced with a
pInducer20 vector containing 3XHA-tagged WT NUDT15.
Cells were induced with 1 μg/ml doxycycline overnight before
compound exposure, followed by heating and lysis in the same
manner as in the CETSA experiments. Proteins were separated
by SDS-PAGE using 4 to 15% Mini-PROTEAN TGX gels and
transferred to nitrocellulose membranes. Membranes were
then incubated with Odyssey Blocking Buffer (LI-COR) and
probed with primary antibodies (anti-NUDT15 antibody, cat.
no. sc-84533, Santa Cruz; anti-SOD1 antibody, cat. no. sc-
11407, Santa Cruz) followed by species-appropriate second-
ary antibodies. Protein bands were visualized with an Odyssey
Fc Imager, and signal intensities were analyzed using Image
Studio Software (Li-Cor Biosciences).
Cell viability assays
Cell viabilities were assayed using the resazurin reduction
cell viability assay, as previously described (22). Briefly, AML
cell lines HL-60 or NB4 were seeded in 384-well assay plates at
50,000/ml and then treated with various concentrations of 6-
TG and/or NUDT15 inhibitors. For NB4 cells conditionally
expressing NUDT15-specific or control shRNAs (22), cells
were induced with doxycycline for 3 days before seeding. Four
days posttreatment, resazurin sodium salt (10 μg/ml) was
added to cells for 4 to 6 h, before resazurin reduction was
assessed via fluorescence intensity at 544/590 nm (Ex/Em)
using a HidexSense plate reader (Hidex). Medium-only and
cell-only wells served as negative (0% cell viability) and positive
(100% cell viability) controls, respectively. Cytotoxicity EC50
values were estimated by fitting cell viabilities via a nonlinear
curve fitting model with variable slope in GraphPad Prism.
Synthesis of TH7755
(R)-6-((2-methyl-4-(1-methyl-1H-indole-5-carbonyl)piper-
azin-1-yl)sulfonyl)benzo[d]oxazol-2(3H)-one (6) was synthe-
sized according to Scheme 1, which is shown in Fig. S4.
Step1: Synthesis of (R)-tert-butyl 3-methyl-4-((2-oxo-2,3-
dihydrobenzo[d]oxazol-6-yl)sulfonyl)piperazine-1-carboxylate
(3).
A solution of 2-oxo-2,3-dihydrobenzo[d]oxazole-6-sulfonyl
chloride (1) (1.0 g; 4.28 mmol) and triethylamine (0.90 ml,
5.42 mmol) in dichloromethane (50 ml) was treated with tert-
butyl piperazine-1-carboxylate (2) (0.86 g, 4.28 mmol) and
stirred at room temperature overnight. The mixture was
diluted with dichloromethane (10 ml) and washed with a
saturated solution of sodium bicarbonate (15 ml). The organic
phase was dried over anhydrous magnesium sulphate then
evaporated to afford the product (3) as a colorless solid which
was used without further purification.
Step 2: Synthesis of (R)-3-methyl-4-((2-oxo-2,3-
dihydrobenzo[d]oxazol-6-yl)sulfonyl)piperazine hydrochlo
ride (4).
A solution of (R)-tert-butyl 3-methyl-4-((2-oxo-2,3-
dihydrobenzo[d]oxazol-6-yl)sulfonyl)piperazine-1-carboxylate
(3) in dioxane (10 ml) was treated with a solution of 4 M HCl
in dioxane (10 ml) and stirred at room temperature overnight.
The mixture was filtered, and the colorless solid was washed
with a little dioxane, then dried overnight. m/z 298 (M + H)+.
The hydrochloride salt (4) was used directly.
Step 3: Synthesis of (R)-6-((2-methyl-4-(1-methyl-1H-
indole-5-carbonyl)piperazin-1-yl)sulfonyl)benzo[d]oxazol-
2(3H)-one (6).
A solution of (R)-3-methyl-4-((2-oxo-2,3-dihydrobenzo[d]
oxazol-6-yl)sulfonyl)piperazine hydrochloride (4) (1.40 g;
4.20 mmol), 1-methyl-1H-indole-5-carboxylic acid (5) (0.74 g;
4.20 mmol), and triethylamine (1.76 ml, 12.6 mmol) in
dichloromethane (50 ml) was treated with propylphosphonic
anhydride (T3P) (1.50 ml; 5.04 mmol) and stirred at room
temperature for 48 h. The reaction mixture was washed with
saturated aqueous sodium bicarbonate (10 ml), then 1 M
aqueous hydrochloric acid (10 ml). The organic extract was
dried over anhydrous magnesium sulphate then evaporated to
give the crude product, which was purified by column chro-
matography over silica (DCM-MeOH; 0–6%) to give the title
compound (6) (280 mg; 15%). 1H NMR (400 MHz, DMSO) δ
7.73 (d, J = 1.6 Hz, 1H), 7.64 (dd, J = 8.2, 1.8 Hz, 1H), 7.57 (s,
1H), 7.46 (d, J = 8.5 Hz, 1H), 7.41 (d, J = 3.1 Hz, 1H), 7.27 (d,
J = 8.2 Hz, 1H), 7.14 (dd, J = 8.5, 1.4 Hz, 1H), 6.48 (dd, J = 3.1,
0.8 Hz, 1H), 4.18 to 3.96 (m, 2H), 3.81 (s, 3H), 3.64 (d, J =
13.1 Hz, 1H), 3.22 to 3.12 (m, 1H), 3.12 to 2.98 (m, 1H), 2.98 to
2.84 (m, 1H), 0.95 (s, 3H). One of the piperazine CH’s is
obscured by DMSO. m/z 455 [M + H]+.
Determination of IC50 values of human and mouse NUDT15
with TH7755
Activity of human and mouse NUDT15 (4.75 nM) was
determined at 22 C in assay buffer (Tris-acetate pH 8.0,
40 mM NaCl, 10 mMMagnesium-acetate, 1 mM DTT, 0.005%
Tween20, 0.2 U/ml PPase) with dGTP (100 μM) as substrate in
the presence of serially diluted TH7755 resulting in final
concentrations ranging from 0 to 10 μM. Duplicate samples
were used for each inhibitor concentration. Pi formed from the
reaction product PPi after hydrolysis by PPase was determined
by addition of a malachite green–based reagent (35) followed
by measurement of the absorbance at 630 nm using a Hidex
plate reader. Controls without NUDT15 were included on the
plate to determine the background signal. Background signal
was subtracted, and % activity was then calculated. IC50 values
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were determined by fitting the equation for “log inhibitor
versus response-variable slope (four parameters)” to the inhi-
bition data using nonlinear regression in GraphPad Prism.
Each experiment was performed twice.
Comparison of activity of WT NUDT15 and NUDT15 mutants
Activity of NUDT15WT (20 nM) and NUDT15 mutants
(20 nM) was assayed with 25 μM 6-thio-dGTP in assay buffer
(Tris-acetate pH 7.5, 40 mM NaCl, 10 mM magnesium-
acetate, 1 mM DTT, 0.2 U/ml PPase). After incubation with
shaking at 22 C for 20 min, the Pi produced from the reaction
product PPi was detected using a malachite green reagent (35)
followed by measurement of the absorbance at 630 nm. Ac-
tivities were assayed in triplicate. Controls lacking NUDT15
enzyme were included on the plate, and the background signal
was subtracted. Activities were normalized to the activity of
NUDT15WT and plotted in GraphPad Prism.
Determination of Ki value and mode of inhibition
Initial rates of NUDT15 (2 nM) were determined in assay
buffer (0.1 M Tris acetate pH 8.0, 40 mM NaCl, 10 mM
magnesium acetate, 1 mM DTT, 0.005% Tween20) over 6-
thio-dGTP concentrations ranging from 0 to 133 μM in
the absence or presence of 15, 45, 135, and 405 nM TH7755.
Each data point was performed in duplicate, and the
experiment was performed twice. PPi produced from 6-thio-
dGTP hydrolysis was detected using PPi Light Inorganic
Pyrophosphate Assay (Lonza), and the signal was converted
to PPi concentration using a PPi standard curve. Initial rates
were plotted against 6-thio-dGTP concentration, and the
Michaelis-Menten equation was fitted to the initial rates
using GraphPad Prism, and the kcat and Km values of
NUDT15 at the different inhibitor concentrations were
determined. To determine the inhibition constant (Ki), the
model for competitive inhibition was fitted to the initial rates
determined at different 6-thio-dGTP and TH7755 concen-
trations using GraphPad Prism.
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